Regresar

Popa X.

Coauthors

Documentos

Volumen de publicaciones por año

Cargando gráfico

Año de publicación	Num. Publicaciones
2011	1
2016	2
2017	1
2020	1

Publicaciones por áreas de conocimiento

Cargando gráfico

Área de conocimiento	Num. Publicaciones
Cáncer	5
Inmunología	4
Medicina interna	1
Medicamento	1

Publicaciones por áreas temáticas

Cargando gráfico

Área temática	Num. Publicaciones
Enfermedades	5
Farmacología y terapéutica	1

Principales fuentes de datos

Origen	Num. Publicaciones
Scopus	5
Google Scholar	0
RRAAE	0

Cargando gráfico

Coautores destacados por número de publicaciones

Coautor	Num. Publicaciones
Tania Crombet	5
García Verdecia B.	4
Luaces P.L.o.	4
Mazorra Z.	4
Neninger Vinageras E.	4
Rodríguez P.C.	3
Carmen Elena Viada	3
Lage Davila A.	3
González A.	2
Fuentes K.P.	2

Cargando gráfico

Top Keywords

Cargando gráfico

Publicaciones del autor

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Article

Abstract: Purpose: There are well-known alterations occurring within the immune system with aging. Collectivel

Palabras claves:

cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancer

Autores:

Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania Crombet

Fuentes:

scopus

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Article

Abstract: The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal

Palabras claves:

Autores:

Carmen Elena Viada, García Verdecia B., González G., Lage Davila A., Luaces P.L.o., Montero E., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania Crombet

Fuentes:

scopus

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

Article

Abstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanc

Palabras claves:

antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarker

Autores:

Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania Crombet

Fuentes:

scopus

Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial

Article

Abstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectiv

Palabras claves:

Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccine

Autores:

Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.

Fuentes:

scopus

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Article

Abstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAv

Palabras claves:

Autores:

Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.

Fuentes:

scopus